跳至主要内容
临床试验/NCT00275704
NCT00275704已完成2 期

Phase II Evaluation of Flaxseed for the Treatment of Hot Flashes

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年5月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Mayo Clinic
入组人数
30
试验地点
1
主要终点
Determine if flaxseed will lower the number and severity of hot flashes

研究概览

简要总结

Flaxseed, a phytoestrogen, is a natural food supplement rich in plant ligands, which have a very weak estrogen effect. In this study, flaxseed is being evaluated in regard to its capacity to safely and effectively treat hot flashes. Specifically, this study seeks to determine if flaxseed will lower the number and severity of hot flashes and if women experience any side effects from taking flaxseed for this purpose.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Inclusionary Criteria:
  • •Age greater than or equal to 18 years
  • •Women with a history of breast cancer (currently without malignant disease) or women who have no history of breast cancer but who wish to avoid estrogen due to a perceived increased risk of breast cancer.
  • •Bothersome hot flashes (defined by occurenece of greater than or equal to 14 times per week and of sufficient severity to make the patient desire therapeutic intervention).
  • •Presence of hot flashes for greater than or equal to 1 month prior to study entry.
  • •Life expectancy greater than or equal to 6 months.
  • •ECOG Performance Status (PS) 0 or 1 (see Appendix VIII)
  • •Exclusionary Criteria/Contraindications
  • •Any of the following current (less than or equal to 4 weeks) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but patient must have been on a constant dose for greater than or equal to 4 weeks and must not be expected to stop the medication during the study period): antineoplastic chemotherapy, androgens, estrogens, progestational agents, other herbal supplements, including soy (herbal teas from a grocery store are allowed), warfarin (1 mg of daily warfarin is allowed for central line patency)
  • •History of allergic or other adverse reaction to flaxseed, wheat, nuts, lactose, and/or certain spices
  • •Current or planned use of other agents for treating hot flashes (except stable dose of vitamine E or antidepressants are allowed as long as they wre started >30 days prior to study initiation and are to be continued through the study period).
  • •Diabetes (as flaxseed can lower blood glucose levels and might have additive effects when used with antidiabetic drugs).
  • •Diagnosis of/problems with chronic diarrhea or history of bowel obstruction or esophageal stricture.
  • •Any of the following: pregnant women, nursing women, women of childbearing potential who are unwilling to employ adequate contraception
  • •Current use of anticoagulants including aspirin, clopidogrel (Plavix), ticlopidine (Ticlic), and coumadin (1 mg of dialy coumadin is allowed for central line patency).
  • •Diagnosis of/problems with von Willebrand's disease or other bleeding disorders.

排除标准

  • 未提供

结局指标

主要结局

Determine if flaxseed will lower the number and severity of hot flashes

Determine if there are any side effects from taking flaxseed for hot flashes

Evaluate the impact of flaxseed on hot flash scores in women with a history of breast cancer or women who do not wish to take estrogen therapy for fear of increased risk of breast cancer.

Evaluate the toxicity of flaxseed in this study population.

Evaluate the effect of flaxseed on quality-of-life measures.

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other

研究点 (1)

Loading locations...

相似试验